OR WAIT 15 SECS
December 09, 2015.
The treatment market for Acute Myeloid Leukemia (AML) will expand in value from $342.7 million in 2014 to $932.6 million by 2024, representing a CAGR of 10.5%, says research and consulting firm GlobalData.
According to the company’s latest report, the increase will primarily be due to the launch of new therapies for AML patients with high unmet needs. GlobalData analyst Sorcha Cassidy says the greatest unmet need in the market is improving the overall survival rate of elderly AML patients which, compared to that of younger favorable-risk patients, is substantially lower.
Cassidy comments: “Fulfilling this unmet need is a safe route to regulatory approval and commercial success. In this way, one of the major drivers of AML treatment sales across the seven majpr markets will be the launch of premium-priced therapies for elderly AML patients, such as Ambit’s quizartinib."
The report also states that by 2024, the branded AML market leader will be Vyxeos, with estimated total sales of $131 million in the US and five European countries.
OpportunityAnalyzer: Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2024